Eduard Louis

Summary

Country: Belgium

Publications

  1. ncbi request reprint Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources
    Edouard Louis
    Gastroenterology Department, CHU of Liege, Brussels, Belgium
    Eur J Gastroenterol Hepatol 14:279-84. 2002
  2. pmc Do clinical factors help to predict disease course in inflammatory bowel disease?
    Edouard Louis
    Department of Gastroenterology, CHU Liege, Liege University, 4000 Liege, Belgium
    World J Gastroenterol 16:2600-3. 2010
  3. pmc Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey
    Stefan Schreiber
    Department of Medicine I, University Hospital Schleswig Holstein, Christian Albrechts University, Kiel, Germany
    BMC Gastroenterol 12:108. 2012
  4. doi request reprint Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial
    Edouard Louis
    University of Liège and CHU, Liege, Belgium
    J Crohns Colitis 7:34-43. 2013
  5. doi request reprint Epidemiology of the transition from early to late Crohn's disease
    Edouard Louis
    Gastroenterology Department, University Hospital of Liege, Liege, Belgium
    Dig Dis 30:376-9. 2012
  6. ncbi request reprint [Genetics and environment in chronic inflammatory bowel diseases]
    E Louis
    Service de Gastroenterologie, CHU de Liege, Belgique
    Rev Med Liege 67:298-304. 2012
  7. ncbi request reprint [Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience]
    E Louis
    Service de Gastroenterologie, CHU de Liege, Belgique
    Rev Med Liege 67:8-13. 2012
  8. doi request reprint What changes in inflammatory bowel disease management can be implemented today?
    Edouard Louis
    Department of Gastroenterology, Centre Hospitalier Universitaire de Liege, Liege, Belgium
    J Crohns Colitis 6:S260-7. 2012
  9. ncbi request reprint Anti-TNF and Crohn's disease: when should we stop?
    Edouard Louis
    Dept of Gastroenterology, CHU Liege, Domaine du Sart Tilman 4000 Liège, Belgium
    Curr Drug Targets 11:148-51. 2010
  10. pmc Are we giving biologics too much time? When should we stop treatment?
    Edouard Louis
    Department of Gastroenterology, CHU Liege, Domaine du Sart Tilman, Liege, Belgium
    World J Gastroenterol 14:5528-31. 2008

Detail Information

Publications56

  1. ncbi request reprint Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources
    Edouard Louis
    Gastroenterology Department, CHU of Liege, Brussels, Belgium
    Eur J Gastroenterol Hepatol 14:279-84. 2002
    ..The specificity of heartburn for the diagnosis of GORD is good. Our aim was to define the prevalence of heartburn in Belgium, characterizing both its impact on everyday life and the ensuing use of medical resources...
  2. pmc Do clinical factors help to predict disease course in inflammatory bowel disease?
    Edouard Louis
    Department of Gastroenterology, CHU Liege, Liege University, 4000 Liege, Belgium
    World J Gastroenterol 16:2600-3. 2010
    ..Besides these important factors, others may predispose to some specific disease evolution and complications, and are also reviewed in the present paper...
  3. pmc Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey
    Stefan Schreiber
    Department of Medicine I, University Hospital Schleswig Holstein, Christian Albrechts University, Kiel, Germany
    BMC Gastroenterol 12:108. 2012
    ..The purpose of this study was to examine the differing perspectives and perceptual gaps relating to ulcerative colitis (UC) symptoms and their management between patients and healthcare professionals (HCPs)...
  4. doi request reprint Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial
    Edouard Louis
    University of Liège and CHU, Liege, Belgium
    J Crohns Colitis 7:34-43. 2013
    ..The population comprised both infliximab-naïve and -exposed patients, including infliximab primary non-responders...
  5. doi request reprint Epidemiology of the transition from early to late Crohn's disease
    Edouard Louis
    Gastroenterology Department, University Hospital of Liege, Liege, Belgium
    Dig Dis 30:376-9. 2012
    ..Third, the correlation between changes in immunobiology and intestinal structural damages has not been specifically studied...
  6. ncbi request reprint [Genetics and environment in chronic inflammatory bowel diseases]
    E Louis
    Service de Gastroenterologie, CHU de Liege, Belgique
    Rev Med Liege 67:298-304. 2012
    ..New therapeutic strategies are currently studied, particularly aiming at targeting immune, inflammatory or homeostatic pathways corresponding to the predisposing gene variants...
  7. ncbi request reprint [Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience]
    E Louis
    Service de Gastroenterologie, CHU de Liege, Belgique
    Rev Med Liege 67:8-13. 2012
    ....
  8. doi request reprint What changes in inflammatory bowel disease management can be implemented today?
    Edouard Louis
    Department of Gastroenterology, Centre Hospitalier Universitaire de Liege, Liege, Belgium
    J Crohns Colitis 6:S260-7. 2012
    ....
  9. ncbi request reprint Anti-TNF and Crohn's disease: when should we stop?
    Edouard Louis
    Dept of Gastroenterology, CHU Liege, Domaine du Sart Tilman 4000 Liège, Belgium
    Curr Drug Targets 11:148-51. 2010
    ....
  10. pmc Are we giving biologics too much time? When should we stop treatment?
    Edouard Louis
    Department of Gastroenterology, CHU Liege, Domaine du Sart Tilman, Liege, Belgium
    World J Gastroenterol 14:5528-31. 2008
    ..Further prospective studies should now aim at disclosing patient characteristics associated with a low risk of relapse to implement this strategy...
  11. ncbi request reprint [Genomics of inflammatory bowel diseases: basis for a new molecular classification and new therapeutic strategies of these diseases]
    E Louis
    Service de Gastroenterologie, CHU de Liege, Liege, Belgique
    Rev Med Liege 64:24-8. 2009
    ..The present paper highlights, in the setting of the Synthèse CHU 2009 meeting, the contributions of the team of the CHU and university of Liège in this field...
  12. pmc Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype
    E Louis
    Department of Gastroenterology, University Hospital of Liege, Belgium
    Gut 52:552-7. 2003
    ..Aim: To assess the association between rapid development of a penetrating or stricturing pattern of Crohn's disease and demographic and clinical characteristics as well as NOD2/CARD15 genotype...
  13. pmc Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease
    E Louis
    Department of Gastroenterology, University Hospital of Liege, Belgium
    Gut 49:777-82. 2001
    ..Clinical classifications of the disease, such as the newly proposed Vienna classification, may help to define subgroups of patients suitable for studying the influence of specific genetic or environmental factors...
  14. ncbi request reprint Atypical symptoms of GORD in Belgium: epidemiological features, current management and open label treatment with 40 mg esomeprazole for one month
    E Louis
    Service de Gastro Enterologie, CHU de Liege, 4000 Liege, Belgique
    Acta Gastroenterol Belg 69:203-8. 2006
    ..Our aims were to set up an observatory of these atypical symptoms of GORD in Belgium and to study the efficacy of one month treatment with esomeprazole 40 mg...
  15. ncbi request reprint Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study
    Edouard J Louis
    Department of Gastroenterology, CHU and University of Liège, Liege, Belgium
    Pharmacogenet Genomics 16:911-4. 2006
    ..3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease...
  16. ncbi request reprint Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT
    Edouard Louis
    Department of Gastroenterology, CHU of Liege, University of Liege, Liege, Belgium
    J Nucl Med 48:1053-9. 2007
    ..Our aim was to assess the use of (18)F-FDG PET/CT in evaluating the activity and location of Crohn's disease along the gastrointestinal tract...
  17. ncbi request reprint Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study
    Eduard Louis
    1 Department of gastroenterology, CHU of Liege, University of Liege, Liege, Belgium
    Acta Gastroenterol Belg 70:15-9. 2007
    ..Stricturing subocclusive small bowel Crohn's disease (CD) is often an indication for surgery. We embarked on an open label pilot study to assess the safety and efficacy of infliximab in patients with stricturing subocclusive CD...
  18. pmc Tailoring the treatment to the individual in Crohn's disease
    Edouard Louis
    Department of Gastroenterology, CHU of Liége and GIGA Research, University of Liege, Belgium
    Therap Adv Gastroenterol 2:239-44. 2009
    ....
  19. doi request reprint Necessity of phenotypic classification of inflammatory bowel disease
    Edouard Louis
    Department of Gastroenterology, University hospital of Liége CHU, Liege University, Liege, Belgium
    Best Pract Res Clin Gastroenterol 25:S2-7. 2011
    ..This subclassification also has a very significant clinical relevance since extensive colitis has been associated with and increased risk of colon cancer, colectomy and even in some studies, mortality...
  20. doi request reprint Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped
    Edouard Louis
    Centre Hospitalier Universitaire de Liege, Liege, Belgium
    Gastroenterology 142:63-70.e5; quiz e31. 2012
    ..We assessed the risk of relapse after infliximab therapy was discontinued in patients on combined maintenance therapy with antimetabolites and identified factors associated with relapse...
  21. doi request reprint Anti-tumor necrosis factor nonresponders in Crohn's disease: therapeutic strategies
    E Louis
    Department of Gastroenterology, CHU of Liege, and GIGA Research, University of Liege, BE 4000 Liege, Belgium
    Dig Dis 27:351-7. 2009
    ..Beyond that, a transient steroid course and surgical procedures still represent rescue option, waiting for new promising biologics in development...
  22. ncbi request reprint A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism
    E Louis
    Dept of Gastroenterology, CHU of Liege, Belgium
    Scand J Gastroenterol 37:818-24. 2002
    ..The aim was to assess the value of C-reactive protein and TNF-alpha serum levels before treatment as well as the TNF -308 gene polymorphism in the prediction of response to infliximab treatment in Crohn disease...
  23. ncbi request reprint Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003
    A Vijverman
    Department of Gastroenterology, CHU of Liege, Belgium
    Acta Gastroenterol Belg 69:1-4. 2006
    ..Our aim was to asses the prevalence and characteristics of anemia among two cohorts of IBD patients at 10 years interval and to look for associated clinical or demographic factors...
  24. ncbi request reprint [Colorectal cancer screening: an absolute necessity and a concrete reality in the French community]
    M Polus
    Service d Hepato Gastroenterologie, CHU de Liege, Belgique
    Rev Med Liege 64:96-102. 2009
    ..A total colonoscopy will be performed if FOBT is positive. First step colonoscopy will be proposed to high or very high risk patients. General practitioners are in the core of the multi-disciplinary program...
  25. ncbi request reprint Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease
    J Belaiche
    Service de Gastroenterologie, CHU Sart Tilman, Liege, Belgium
    Scand J Gastroenterol 36:71-6. 2001
    ..The aims of the study were to evaluate the RBC 6TGN concentrations in adult patients with CD under long-term AZA/6-MP therapy and to correlate it with response to treatment and haematological parameters...
  26. ncbi request reprint [Therapeutic update in gastroenterology]
    J Belaiche
    Service d Hepato Gastroenterologie, CHU Sart Tilman, ULg, Liege
    Rev Med Liege 62:303-9. 2007
    ..New algorithms in inflammatory bowel diseases, chronic hepatitis C and digestive oncology are examples of the marked progress achieved by these therapies...
  27. ncbi request reprint Use of the enteroscope for colo-ileoscopy: low yield in unexplained lower gastrointestinal bleeding
    J Belaiche
    Dept of Gastroenterology, Centre Hospitalier Universitaire Sart Tilman, University of Liege, Belgium
    Endoscopy 31:298-301. 1999
    ..The aim of this study was to assess the benefit of lower gastrointestinal tract enteroscopy in occult digestive bleeding...
  28. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  29. ncbi request reprint Diagnosis of small bowel malabsorption syndromes in adults
    J Belaiche
    Department of Gastroenterology, CHU Sart Tilman, Liege, Belgium
    Acta Gastroenterol Belg 69:31-7. 2006
    ..This strategy has largely supplanted many older tests of small bowel function...
  30. ncbi request reprint Development of adenocarcinoma in chronic fistula in Crohn's disease
    S Laurent
    Dpt of Abdominal Surgery, CHU Sart Tilman B35, B 4000 Liege, Belgium
    Acta Gastroenterol Belg 68:98-100. 2005
    ..Secondarily, radiochemotherapy was administrated. The authors discuss the incidence and risk factors of carcinoma in Crohn's disease with chronic fistulas...
  31. ncbi request reprint Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease
    N Esters
    Department of Gastroenterology, UZ Gasthuisberg Leuven, Belgium
    Am J Gastroenterol 97:1458-62. 2002
    ..Our aim was to determine whether serological markers ASCA (anti-Saccharomyces cerevisiae antibodies) or pANCA (perinuclear antineutrophil cytoplasmic antibodies) could identify Crohn's patients likely to benefit from anti-TNF therapy...
  32. ncbi request reprint [Proteomics studies on arthritis by SELDI-TOF-MS: identification of the S100 proteins family as proteins of interest]
    D de Seny
    Service de Rhumatologie, CHU de Liege, Liege, Belgique
    Rev Med Liege 64:29-35. 2009
    ..This work was presented in the setting of the "Synthèse CHU 2009" meeting...
  33. ncbi request reprint [PPI very long-term treatment: is the problem only economic?]
    M Vanmeerbeek
    Département de médecine générale, Universite de Liege, Belgique
    Rev Med Liege 61:483-7. 2006
    ..Simple lifestyle advice is still useful. The burden of proton pump inhibitors cost is acceptable if they are prescribed at adequate doses. Cost-effective drugs should be chosen first...
  34. ncbi request reprint [Primary and secondary prevention of colorectal cancer]
    M Polus
    Service d Oncologie Medicale, CHU Liege
    Rev Med Liege 58:247-53. 2003
    ..Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality...
  35. ncbi request reprint Negative association between smoking and anti-saccharomyces cerevisiae antibodies in Crohn's disease
    C Van Kemseke
    Department of Gastroenterology, Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium
    Acta Gastroenterol Belg 66:1-6. 2003
    ..The reason for ASCA positivity or negativity in CD is unknown. The aim of our work was to analyse clinical, epidemiological and genetic characteristics in ASCA+ or ASCA- CD patients...
  36. ncbi request reprint Strictureplasty in Crohn's disease: short- and long-term follow-up
    S Laurent
    Dpt of Abdominal Surgery, CHU Sart Tilman B 35, Liege, Belgium
    Acta Chir Belg 102:253-5. 2002
    ..These results confirmed that strictureplasty is a safe and efficient procedure in selected patients undergoing surgery for obstructive Crohn's disease...
  37. ncbi request reprint Ileo-caecal actinomycosis: report of a case simulating complicated inflammatory bowel disease
    A Postal
    Department of Abdominal Surgery, , CHU Sart Tilman B35, , Belgium
    Acta Gastroenterol Belg 64:318-20. 2001
    ..This case demonstrated that abdominal actinomycosis should be included in the differential diagnosis when computed tomography shows an infiltrative and inflammatory mass...
  38. ncbi request reprint [Pharma-clinics medication of the month. Rabeprazole (Pariet)]
    E Louis
    Service de Gastroenterologie, CHU de Liege
    Rev Med Liege 57:53-6. 2002
    ..Controlled studies have shown an efficacy similar to emeprazole in the treatment of oeso-gastro-duodenal acid diseases. Rabeprazole has a favourable profile with rapid action and good safety...
  39. ncbi request reprint The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha
    E Louis
    Department of Gastroenterology, CEMIC (Centre d'Etude des Maladies Inflammatoires Chroniques, , , Belgium
    Acta Gastroenterol Belg 64:1-5. 2001
    ..Following points are developed: production of TNF by inflamed mucosa, genetic control of TNF production, TNF gene polymorphim in inflammatory bowel disease, and evaluation of serum TNF as a marker of disease activity or evolutivity...
  40. ncbi request reprint [Pharma clinics medication of the month. Esomeprazole]
    E Louis
    Service de Gastroenterologie, CHU de Liege
    Rev Med Liege 57:610-2. 2002
    ....
  41. ncbi request reprint Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
    E Louis
    Department of Gastroenterology, CHU of Liege, Liege, Belgium
    Aliment Pharmacol Ther 19:511-9. 2004
    ....
  42. pmc Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients
    N Franchimont
    Rheumatology Department, University of Liege, CHU Sart Tilman, 4000 Liege, Belgium
    Clin Exp Immunol 138:491-8. 2004
    ..Moreover, RANK is expressed in the colonic mucosa by subpopulations of activated macrophages or dendritic cells at higher levels in CD compared to normal colon...
  43. ncbi request reprint Video capsule endoscopy in small-bowel malignancy: a multicenter Belgian study
    D Urbain
    Hepato Gastroenterology Unit, Vrije Universiteit van Brissel, AZ VUB, Brussels, Belgium
    Endoscopy 38:408-11. 2006
    ..The aim of this paper was to review all capsule endoscopy findings at Belgian hospitals, in order to evaluate the diagnostic yield of capsule endoscopy in the field of small-bowel malignancy...
  44. ncbi request reprint Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
    N Franchimont
    Rheumatology Department, CHU Liege, Belgium
    Aliment Pharmacol Ther 20:607-14. 2004
    ..Crohn's disease is associated with low bone mineral density and altered bone metabolism...
  45. ncbi request reprint [Screening for colorectal cancer]
    P Piront
    Service de Gastroenterologie, CHU Sart Tilman, CBIG GIGA, ULg Liège, Belgique
    Rev Med Liege 62:15-20. 2007
    ..New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum...
  46. pmc Altered expression of type I insulin-like growth factor receptor in Crohn's disease
    F El Yafi
    Department of Gastroenterology, CHU of Liege, Liege, Belgium
    Clin Exp Immunol 139:526-33. 2005
    ..We have shown a transmural altered expression of IGF-1R in CD. This may suggest a role for IGF-1R in the maintenance of chronic inflammation and stricture formation in CD...
  47. ncbi request reprint [Biologic therapies in chronic inflammatory bowel diseases]
    C Reenaers
    Universite de Liege, CHU de Liege, Belgique
    Rev Med Liege 64:301-4. 2009
    ..Ustekinumab generates favourable clinical responses in Crohn's disease. The development of biologic therapies in inflammatory bowel disease has dramatically altered the course and management of these disorders...
  48. ncbi request reprint Evaluation of the GERD Impact Scale, an international, validated patient questionnaire, in daily practice. Results of the ALEGRIA study
    E Louis
    Department of Gastroenterology, CHU of Liege, Belgium
    Acta Gastroenterol Belg 72:3-8. 2009
    ..This study gathered epidemiological data in a population of GERD patients and evaluated the added-value of the GERD Impact Scale (GIS), a novel, validated patient questionnaire, as a tool for initial and long-term patient management...
  49. ncbi request reprint Observational survey of NSAID-related upper gastro-intestinal adverse events in Belgium
    J Belaiche
    Department of Gastroenterology, CHU Sart Tilman, Liege, Belgium
    Acta Gastroenterol Belg 65:65-73. 2002
    ..To evaluate the impact of NSAID use on current routine upper GI endoscopy (UGIE) and to compare the lesions found in NSAID users and non-users...
  50. ncbi request reprint [Innovative therapies in inflammatory bowel disease at the CHU]
    J Belaiche
    Service d Hepato Gastroenterologie, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 62:63-7. 2007
    ....
  51. ncbi request reprint Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor
    D Franchimont
    Department of Gastroenterology CHU, University of Liege, Belgium
    J Clin Endocrinol Metab 84:2834-9. 1999
    ..This study suggests that the pattern of pro-/antiinflammatory cytokine secretion may alter the response of patients to glucocorticoid therapy...
  52. ncbi request reprint Increased response of blood eosinophils to various chemotactic agents in quiescent Crohn disease
    M A Denis
    Dept. of Gastroenterology, , Belgium
    Scand J Gastroenterol 36:190-5. 2001
    ..This may participate in the mucosal infiltration by eosinophils in this disease...
  53. ncbi request reprint Intercellular contacts between germinal center cells. Mechanisms of adhesion between lymphoid cells and follicular dendritic cells
    E Louis
    Institute of Human Histology, University of Liege, Belgium
    Acta Otorhinolaryngol Belg 43:297-320. 1989
    ..This antigen thus seems to play a role in the intercellular contacts; this is the first function ascribed to this FDC specific antigen...
  54. ncbi request reprint Pregnancy and inflammatory bowel disease
    E Louis
    Service de Gastroenterologie, CHU de Liege, Domaine du Sart Tilman, 4000 Liege, Belgium
    Acta Gastroenterol Belg 65:230-2. 2002
    ....
  55. doi request reprint Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings
    H Piessevaux
    Department of Gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium
    Neurogastroenterol Motil 21:378-88. 2009
    ..If forced in a four-factor model, the analysis separates belching as independent factor. Dyspeptic symptoms are frequent in the general population, with overlapping reflux symptoms and increased symptom burden in about a third...
  56. ncbi request reprint Effects of proglumide and enprostil on omeprazole-induced fundic endocrine cell hyperplasia in rats
    J Delwaide
    Service de Gastroenterologie, CHU Sart Tilman, Liege
    Gastroenterol Clin Biol 17:792-6. 1993
    ..These results indicate that proglumide, but not enprostil, can counteract the omeprazole-induced argyrophil cell hyperplasia in rats...